Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
Conditions: COVID-19 Interventions: Drug: CD40.RBDv vaccin (SARS-Cov2 Vaccin) Sponsors: ANRS, Emerging Infectious Diseases; LinKinVax; Vaccine Research Institute (VRI), France Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Covid Vaccine | COVID-19 | France Health | Infectious Diseases | Research | SARS | Vaccines